Current Report Filing (8-k)
April 29 2016 - 7:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 29, 2016 (April 29, 2016)
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
British Columbia, Canada
|
|
001-14956
|
|
98-0448205
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
file number)
|
|
(IRS Employer
Identification No.)
|
2150 St. Elzéar Blvd. West, Laval, Quebec, Canada H7L 4A8
(Address of principal executive offices) (Zip Code)
(514) 744-6792
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On April 29, 2016, Valeant
Pharmaceuticals International, Inc. (the Company) issued a press release with respect to the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which includes consolidated financial statements
for the years ended December 31, 2013, 2014 and 2015. The audited consolidated financial statements for the year ended December 31, 2014 are restated. The Company has also restated certain unaudited quarterly results related to the three
months ended December 31, 2014, the three months ended March 31, 2015, the six months ended June 30, 2015 and the nine months ended September 30, 2015 and revised certain unaudited results for the three months and nine months
ended September 30, 2014. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Valeant Pharmaceuticals International, Inc. dated April 29, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: April 29, 2016
|
|
|
|
|
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
|
|
|
By:
|
|
/s/ Robert L. Rosiello
|
|
|
Robert L. Rosiello
|
|
|
Executive Vice President, Chief Financial Officer
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Valeant Pharmaceuticals International, Inc. dated April 29, 2016
|
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2023 to Apr 2024